Pharmaceuticals & Therapeutics

NRx Pharmaceuticals gets a green light from the FDA to seek broader approval for its ketamine drug, NRX-100, using a novel real-world evidence approach.

Cyclerion's novel therapy for treatment-resistant depression, using EEG-guided anesthesia, gains key FDA support and a top-tier advisory board.

Landmark Phase 3 trial results show psilocybin offers rapid, lasting relief for severe depression, pushing psychedelic medicine closer to the mainstream.

New long-term data shows duvakitug maintained remission in IBD patients for nearly a year, positioning it as a top contender in a new class of therapy.

With a bolstered cash runway from recent funding, Inventiva is all-in on its MASH drug, lanifibranor, racing against giants in a multi-billion dollar market.

A new study uses PET-CT scans to track CIT-013, a first-in-class antibody targeting the root cause of inflammation in rheumatoid arthritis and HS.

With a novel glutamate-targeting drug and a €38M cash injection, Newron aims to transform care for treatment-resistant schizophrenia.

Atlanta's World Neuroscience Day Conference returns to explore the brain-heart connection, demystify clinical trials, and empower a growing community.

A genomic test identifies which breast cancer patients truly benefit from extended hormone therapy, a major step toward personalized long-term care.

A new genomics tracker reveals the fragmented adoption of precision cancer care across the EU-5, highlighting critical barriers and strategic opportunities.

Acurx Pharmaceuticals preps for pivotal Phase 3 trials for its novel C. diff antibiotic, Ibezapolstat, with global regulatory alignment in place.

Zemcelpro® gains key reimbursement status, offering immediate hope and access for German patients with limited options and paving a new path for cell therapy.

After a 1,000% stock surge on promising clinical data, Nektar Therapeutics secures $460M, fueling its next chapter in immunotherapy amid high hopes and risks.

Elanco's founding chairman and innovation head are leaving, marking a pivotal leadership shift as the animal health giant charts its post-spin-off future.

The biotech firm enacts a 1-for-25 stock split to avoid delisting, placing its promising cancer therapy pipeline under a brighter, more critical spotlight.

With a $15 million funding boost, Nasus Pharma is accelerating its powder-based intranasal epinephrine, NS002, challenging the EpiPen's dominance.

Iterum Therapeutics secures key Medicare access for its antibiotic ORLYNVAH™, but a costly FDA trial requirement for a new use casts a shadow on its future.

Alto Neuroscience completes enrollment for a trial of its skin patch drug, ALTO-101, offering new hope for the millions battling cognitive decline in schizophrenia.

The firm behind a controversial drug-permissive sporting event is hitting Wall Street via a SPAC, challenging the ethics of global anti-doping standards.

Anebulo Pharmaceuticals is delisting from Nasdaq to focus on a pediatric cannabis antidote, leaving investors to grapple with an uncertain future.